• The narrow-spectrum macrocyclic antibiotic fidaxomicin has been associated with both greater...

• Eligible patients were...

• EXTEND was an open-label, randomised, active-comparator controlled, parallel-group, Phase III/IV...

• A SCC was defined as clinical response at test of cure (TOC) with no subsequent CDI recurrence

• Secondary endpoints included in this analysis were:

• Findings from a validated

• Oliver A. Cornely MD,1,2 Maria J.G.T. Vehreschild MD,1,2 Nicholas Adomakoh MBBS,3 Areti Georgopali MD,3 Andreas Karas MD,3 Gbenga Kazeem PhD,3 Benoit Guery MD4

• The Efficacy of Extended-Pulsed Fidaxomicin with Standard Vancomycin Therapy for Sustained Clinical Cure of Clostridium difficile – Cancer diagnosis (presence versus absence), and

• Clinical response at Day 12 and 2 days after EOT

• Asymptomatic Clostridium difficile – Toxin A or B in stool within 48 hours of collection devices) within 24 hours of randomisation, plus ≥

• OBJECTIVE

• EPFX was associated with a significantly higher rate of SCC than vancomycin in patients with PCR-

• The overall safety outcomes of EXTEND have been described elsewhere7

• The authors thank the EXTEND study group for their important contributions to this work. The study...